Efficacy and safety study of rivaroxaban for head and neck venous thromboembolism patients
OBJECTIVE To explore the clinical efficacy and safety of rivaroxaban for head and neck venous thromboembo-lism(VTE).METHODS From December 2015 to January 2022,for this retrospective cohort study,291 patients with head and neck VTE were recruited at Nanjing Drum Tower Hospital.Based upon specific anticoagulants,they were assigned into two groups of warfarin and rivaroxaban.Follow-up period was at least 2 years.Baseline profiles,recurrent VTE and bleeding events were recorded for two groups.Inverse probability of treatment weighting(IPTW)was employed for balancing the inter-group dif-ferences in baseline profiles.Kaplan-Meier curve and multivariate COX proportional hazard model were utilized for comparing the inter-group differences in recurrent VTE and bleeding events.RESULTS After stable IPTW,there was no significant inter-group difference in baseline profiles.And no statistically significant inter-group difference existed in rates of recurrent VTE,all bleeding events and major bleeding events(HR=0.64,95％CI:0.30-1.31;HR=0.47,95％CI:0.20-1.11;HR=0.65,95％CI:0.23-1.85).Renal function hinted at significant interaction with treatment group in terms of all bleeding events and major bleeding events(P=0.012;P=0.048).CONCLUSION Rivaroxaban has similar anticoagulation efficacy and safety to warfarin in patients with head and neck VTE.
head and neck venous thromboembolismwarfarinrivaroxabanefficacysafety
NETL
NSTL
万方数据
